B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PIK3C2G

MOLECULAR TARGET

phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma

UniProt: O75747NCBI Gene: 52886 compounds

PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PIK3C2G

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1lapatinib4.84126
2pi 1034.1764
3midostaurin3.8546
4lestaurtinib3.0420
5tg100 1152.087
6pictilisib0.691

About PIK3C2G as a Drug Target

PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented PIK3C2G interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PIK3C2G inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.